Long-term outcome and prognostic factors for patients with para-aortic lymph node dissection in left-sided colorectal cancer.
Colorectal cancer
Lymph node dissection
Metastasis
Para-aortic lymph node
Prognosis
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
accepted:
05
04
2019
pubmed:
3
5
2019
medline:
16
11
2019
entrez:
3
5
2019
Statut:
ppublish
Résumé
Para-aortic lymph node (PALN) metastasis of colorectal cancer is rare, and the treatment strategy for PALN metastasis (PALNM) is not established in contrast to liver or lung metastases. We sought to evaluate the survival outcomes and prognostic factors among patients undergoing surgery combined with extended lymphadenectomy for PALNM from left-sided colorectal cancer. From 1992 to 2012, 322 patients who underwent PALN dissection (PALND) synchronously with primary resection, among 1819 left-sided colorectal surgical cases, were retrospectively examined. We investigated the overall survival (OS) and prognostic factors for patients with PALNM. Of the 322 patients, 62 (19.3%) were histologically confirmed to have PALNM. The 5-year OS in patients with and without PALNM was 19.5% and 67.0% (p < 0.001), respectively. Among patients with PALNM, on the multivariable analysis, the positive resection margin (hazard ratio (HR) 3.61; 95% confidence interval (CI) 1.85-7.06), undifferentiated histological type ((por/muc/sig), HR 4.51; 95% CI, 2.22-9.19), ≥ 4 PALNMs (HR 3.34; 95% CI 1.53-7.31), and preoperative CEA ≥ 10 ng/mL (HR 2.1; 95% CI 1.11-4.27) were significant prognostic factors. Among R0 resected cases, the 5-year OS of the 17 cases with ≤ 3 PALNM and well/moderately differentiated adenocarcinoma was 54.2%, which was comparable to that of patients undergoing PALND and diagnosed with stage IIIC (49.6%). Patients with PALNM of colorectal cancer had a poor prognosis. However, curative resection, ≤ 3 PALNM, and well/moderately differentiated histology type were associated with the long-term survival.
Sections du résumé
BACKGROUND
BACKGROUND
Para-aortic lymph node (PALN) metastasis of colorectal cancer is rare, and the treatment strategy for PALN metastasis (PALNM) is not established in contrast to liver or lung metastases. We sought to evaluate the survival outcomes and prognostic factors among patients undergoing surgery combined with extended lymphadenectomy for PALNM from left-sided colorectal cancer.
METHODS
METHODS
From 1992 to 2012, 322 patients who underwent PALN dissection (PALND) synchronously with primary resection, among 1819 left-sided colorectal surgical cases, were retrospectively examined. We investigated the overall survival (OS) and prognostic factors for patients with PALNM.
RESULTS
RESULTS
Of the 322 patients, 62 (19.3%) were histologically confirmed to have PALNM. The 5-year OS in patients with and without PALNM was 19.5% and 67.0% (p < 0.001), respectively. Among patients with PALNM, on the multivariable analysis, the positive resection margin (hazard ratio (HR) 3.61; 95% confidence interval (CI) 1.85-7.06), undifferentiated histological type ((por/muc/sig), HR 4.51; 95% CI, 2.22-9.19), ≥ 4 PALNMs (HR 3.34; 95% CI 1.53-7.31), and preoperative CEA ≥ 10 ng/mL (HR 2.1; 95% CI 1.11-4.27) were significant prognostic factors. Among R0 resected cases, the 5-year OS of the 17 cases with ≤ 3 PALNM and well/moderately differentiated adenocarcinoma was 54.2%, which was comparable to that of patients undergoing PALND and diagnosed with stage IIIC (49.6%).
CONCLUSION
CONCLUSIONS
Patients with PALNM of colorectal cancer had a poor prognosis. However, curative resection, ≤ 3 PALNM, and well/moderately differentiated histology type were associated with the long-term survival.
Identifiants
pubmed: 31044284
doi: 10.1007/s00384-019-03294-2
pii: 10.1007/s00384-019-03294-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1121-1129Références
Dis Colon Rectum. 2002 Apr;45(4):468-73; discussion 473-5
pubmed: 12006927
Anticancer Res. 2003 Sep-Oct;23(5b):4181-6
pubmed: 14666622
J Gastrointest Surg. 2005 Jul-Aug;9(6):781-8
pubmed: 15985233
J Clin Oncol. 2009 Jul 1;27(19):3109-16
pubmed: 19451431
J Surg Oncol. 2010 Jan 1;101(1):66-71
pubmed: 19842140
J Clin Oncol. 2011 Oct 1;29(28):3768-74
pubmed: 21859995
Int J Clin Oncol. 2012 Feb;17(1):1-29
pubmed: 22002491
World J Surg. 2012 Sep;36(9):2171-8
pubmed: 22547015
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Lancet Oncol. 2015 Aug;16(8):979-89
pubmed: 26189067
Dig Surg. 2015;32(6):439-44
pubmed: 26402333
Ann Surg Oncol. 2016 May;23(5):1562-8
pubmed: 26714940
Asian J Surg. 2017 Jul;40(4):254-261
pubmed: 26776452
Ann Surg Treat Res. 2016 Jan;90(1):29-35
pubmed: 26793690
Surg Oncol. 2016 Dec;25(4):411-418
pubmed: 27916174
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Int J Clin Oncol. 2018 Feb;23(1):1-34
pubmed: 28349281
Int J Colorectal Dis. 2017 Jul;32(7):999-1007
pubmed: 28382511
Cancer Res Treat. 2018 Jul;50(3):712-719
pubmed: 28707461
Dig Surg. 2018 Jul 25;:1-7
pubmed: 30045044